Ratings CKD Corporation

Equities

6407

JP3346800000

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 EDT			5-day change	1st Jan Change
2,938 ^JPY	+1.73%		+1.70%	+15.67%

04-15	AstraZeneca: expects a sharp rise in kidney disease	CF
04-11	TVS Supply Chain's Supply of CKD Kits to TVS Motor Crosses 500,000	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Over the past four months, analysts' average price target has been revised upwards significantly.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Industrial Machinery & Equipment

	1st Jan change	Capi.	ESG Refinitiv
CKD CORPORATION	+15.67%	1.25B	-
NORDSON CORPORATION	-1.42%	14.89B	B
HAITIAN INTERNATIONAL HOLDINGS LIMITED	+25.00%	4.92B	B
WUXI LEAD INTELLIGENT EQUIPMENT CO.,LTD.	-14.84%	4.68B	C+
VALMET OYJ	-11.99%	4.52B	C+
KRONES AG	+10.91%	4.18B	B-
SUZHOU MAXWELL TECHNOLOGIES CO., LTD.	-17.31%	4.12B	C
TOMRA SYSTEMS ASA	+13.00%	3.73B	B-
IHI CORPORATION	+29.08%	3.43B	A-
KADANT INC.	+0.73%	3.31B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes